CalciMedica Share Price
NASDAQ: CALC | Micro Cap | HealthcareCalciMedica Stock Performance
CalciMedica Share Price Chart
CalciMedica Quarterly Profit & Loss
All figures in USD
CalciMedica Annual Profit & Loss
All figures in USD
CalciMedica Balance Sheet
All figures in USD Million
CalciMedica Cash Flow
All figures in USD Million
Corporate Actions
About CalciMedica
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
CalciMedica Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $1.48 | $1.26 | -27.17% |
Oct 2026 | $1.64 | $1.73 | +6.46% |
Sep 2026 | $2.13 | $1.63 | +247.22% |
Aug 2026 | $0.96 | $0.47 | -52.24% |
Jul 2026 | $0.98 | $0.98 | +0.20% |
Jun 2026 | $0.85 | $0.98 | +25.38% |
May 2026 | $0.61 | $0.78 | +36.84% |
Apr 2026 | $0.59 | $0.57 | +5.56% |
Mar 2026 | $0.49 | $0.54 | +4.25% |
Feb 2026 | $0.78 | $0.52 | -42.12% |
Jan 2026 | $6.63 | $0.90 | -86.56% |
Dec 2025 | $4.34 | $6.66 | +57.82% |